Defining mechanisms of mycobacterial protective immunity using human experimental medicine and murine models (360G-Wellcome-206331_Z_17_Z)
Progress in the development of an effective TB vaccine is hindered by an incomplete understanding of protective immunity, and by a lack of knowledge as to which proteins from Mycobacterium tuberculosis (M.tb) are protective. Most of our understanding has come from studies in mice, and studies using blood from patients with TB. The lung is the primary site of infection in TB. Lung and blood responses may differ, and murine and human responses can also differ. I have developed a safe human infection model in which BCG, a replicating mycobacterial strain, is delivered by aerosol directly to the lungs of healthy volunteers. I will use this model to define the innate and adaptive, systemic and mucosal immune responses, in humans. I will then use an in-vitro mycobacterial growth inhibition assay to assess whether these responses are protective. I will use this information to identify which components of host immunity are important in protection in humans. We will also use state-of-the-art mass spectrometry to identify which M.tb proteins are naturally presented to the human immune system, and determine if these proteins confer protection in a murine M.tb challenge study. This information will facilitate the development of effective vaccines.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 1953582 |
Applicant Surname | McShane |
Approval Committee | Science Interview Panel |
Award Date | 2017-04-05T00:00:00+00:00 |
Financial Year | 2016/17 |
Grant Programme: Title | Investigator Award in Science |
Internal ID | 206331/Z/17/Z |
Lead Applicant | Prof Helen McShane |
Partnership Value | 1953582 |
Planned Dates: End Date | 2024-06-30T00:00:00+00:00 |
Planned Dates: Start Date | 2017-07-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South East |